Induction of an embryonic globin gene promoter by short-chain fatty acids

Blood

Volumn 102, Issue 12, 2003, Pages 4214-4222

  Dempsey, Nancy J ^b   Ojalvo, Laureen S ^b   Wu, Davina W ^b   Little, Jane A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GLOBIN; HISTONE ACETYLTRANSFERASE; PROTEIN P300; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3;

ACETYLATION; ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; EMBRYO DEVELOPMENT; ERYTHROLEUKEMIA CELL; FATTY ACID METABOLISM; GENE INDUCTION; GLOBIN GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION;

EID: 0344826011     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-12-3766     Document Type: Article

References (73)

1. Wood WG, Clegg JB, Weatherall DJ. Hereditary persistence of fetal haemoglobin (HPFH) and δβ thalassaemia. Br J Haematol. 1979;43:509-520.
2. Poillon WN, Kim BC, Rodgers GP, Noguchi CT, Schechter AN. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci U S A. 1993;90:5039-5043.
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
4. Ley TJ. The pharmacology of hemoglobin switching: of mice and men. Blood. 1991;77:1146-1152.
5. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of buryrate to stimulate fetal-globingene expression in the β-globin disorders. N Engl J Med. 1993;328:81-86.
6. Collins AF, Pearson HA, Giardina P, McDonagh T, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous β thalassemia: a clinical trial. Blood. 1995;85:43-49.
7. Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF. Extended therapy with intravenous arginine butyrate in patients with β -hemoglobinopathies [Comment appears in N Engl J Med. 1995;333:1287-1288]. N Engl J Med. 1995;332:1606-1610.
8. Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF. Extended therapy with intravenous arginine butyrate in patients with β -hemoglobinopathies [Comment appears in N Engl J Med. 1995;333:1287-1288]. N Engl J Med. 1995;332:1606-1610.
9. Cappellini MD, Graziadei G, Ciceri L, et al. Butyrate trials. Ann N Y Acad Sci. 1998;850:110-119.
10. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease [Comment appears in Blood. 1999;93:1787-1789]. Blood. 1999;93:1790-1797.
11. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease [Comment appears in Blood. 1999;93:1787-1789]. Blood. 1999;93:1790-1797.
12. Galanello R, Cao A, Olivieri N. Induction of fetal hemoglobin in the presence of increased 3-hydroxybutyric acid associated with β-ketothiolase deficiency. N Engl J Med. 1994;331:746-747.
13. Perrine SP, Greene MF, Faller DV. Delay in the fetal globin switch in infants of diabetic mothers. N Engl J Med. 1985;312:334-338.
14. Little JA, Dempsey NJ, Tuchman M, Ginder GD. Metabolic persistence of fetal hemoglobin. Blood. 1995;85:1712-1718.
15. Jahn CL, Hutchison CA III, Phillips SJ, et al. DNA sequence organization of the β-globin complex in the BALB/c mouse. Cell. 1980;21:159-168.
16. Hill A, Hardies SC, Phillips SJ, Davis MG, Hutchison CA III, Edgell MH. Two mouse early embryonic β-globin gene sequences: evolution of the nonadult beta-globins. J Biol Chem. 1984;259:3739-3747.
17. Leder A, Leder P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell. 1975;5:319-322.
18. Morley BJ, Abbott CA, Wood WG. Regulation of human fetal and adult globin genes in mouse erythroleukemia cells. Blood. 1991;78:1355-1363.
19. Skarpidi E, Vassilopoulos G, Stamatoyannopoulos G, Li Q. Comparison of expression of human globin genes transferred into mouse erythroleukemia cells and in transgenic mice. Blood. 1998;92:3416-3421.
20. Epner E, Reik A, Cimbora D, et al. The β-globin LCR is not necessary for an open chromatin structure or developmentally regulated transcription of the native mouse β-globin locus. Mol Cell. 1998;2:447-455.
21. Grosveld F. Activation by locus control regions? Curr Opin Genet Dev. 1999;9:152-157.
22. Grosveld F, Antoniou M, Berry M, et al. The regulation of human globin gene switching. Philos Trans R Soc Lond B Biol Sci. 1993;339:183-191.
23. Miller IJ, Bieker JJ. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Krüppel family of nuclear proteins. Mol Cell Biol. 1993;13:2776-2786.
24. Crossley M, Whitelaw E, Perkins A, Williams G, Fujiwara Y, Orkin SH. Isolation and characterization of the cDNA encoding BKLF/TEF-2, a major CACCC-box-binding protein in erythroid cells and selected other cells. Mol Cell Biol. 1996;16:1695-1705.
25. Asano H, Li XS, Stamatoyannopoulos G. FKLF, a novel Kruppel-like factor that activates human embryonic and fetal β-like globin genes. Mol Cell Biol. 1999;19:3571-3579.
26. Asano H, Li XS, Stamatoyannopoulos G. FKLF-2: a novel Kruppel-like transcriptional factor that activates globin and other erythroid lineage genes. Blood. 2000;95:3578-3584.
27. Moon AM, Ley TJ. Conservation of the primary structure, organization, and function of the human and mouse beta-globin locus-activating regions. Proc Natl Acad Sci U S A. 1990;87:7693-7697.
28. Zhang W, Bieker JJ. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sci U S A. 1998;95:9855-9860.
29. Armstrong JA, Bieker JJ, Emerson BM. A SWI/SNF-related chromatin remodeling complex, ERC1, is required for tissue-specific transcriptional regulation by EKLF in vitro. Cell. 1998;95:93-104.
30. Zhang W, Kadam S, Emerson BM, Bieker JJ. Site-specific acetylation by p300 or CREB binding protein regulates erythroid Kruppel-like factor transcriptional activity via its interaction with the SWI-SNF complex. Mol Cell Biol. 2001;21:2413-2422.
31. Bieker JJ. Isolation, genomic structure, and expression of human erythroid Kruppel-like factor (EKLF). DNA Cell Biol. 1996;15:347-352.
32. Hagen G, Muller S, Beato M, Suske G. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J. 1994;13:3843-3851.
33. Berger J, Hauber J, Hauber R, Geiger R, Cullen BR. Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene. 1988;66:1-10.
34. Glauber JG, Wandersee NJ, Little JA, Ginder GD. 5′-flanking sequences mediate butyrate stimulation of embryonic globin gene expression in adult erythroid cells. Mol Cell Biol. 1991;11:4690-4697.
35. Xiao H, Hasegawa T, Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem. 1999;73:291-302.
36. Shapiro DJ, Sharp PA, Wahli WW, Keller MJ. A high-efficiency HeLa cell nuclear transcription extract. DNA. 1988;7:47-55.
37. Song CZ, Keller K, Murata K, Asano H, Stamatoyannopoulos G. Functional interaction between coactivators CBP/p300, PCAF, and transcription factor FKLF2. J Biol Chem. 2002;277:7029-7036.
38. Forsberg EC, Johnson K, Zaboikina TN, Mosser EA, Bresnick EH. Requirement of an E1A-sensitive coactivator for long-range transactivation by the β-globin locus control region. J Biol Chem. 1999;274:26850-26859.
39. Gordon M-J, Crabtree B. The effects of propionate and butyrate on acetate metabolism in rat hepatocytes. Int J Biochem. 1992;24:1029-1031.
40. Stamatoyannopoulos G, Blau CA, Nakamoto B, et al. Fetal hemoglobin induction by acetate, a product of butyrate catabolism [Comment appears in Blood. 1995;85:3765-3566]. Blood. 1994;84:3198-3204.
41. Stamatoyannopoulos G, Blau CA, Nakamoto B, et al. Fetal hemoglobin induction by acetate, a product of butyrate catabolism [Comment appears in Blood. 1995;85:3765-3566]. Blood. 1994;84:3198-3204.
42. Pace BS, Li Q, Stamatoyannopoulos G. In vivo search for butyrate responsive sequences using transgenic mice carrying A gamma gene promoter mutants. Blood. 1996;88:1079-1083.
43. McCaffrey PG, Newsome DA, Fibach E, Yoshida M, Su MS. Induction of γ-globin by histone deacetylase inhibitors. Blood. 1997;90:2075-2083.
44. Ikuta T, Kan YW, Swerdlow PS, Faller DV, Perrine SP. Alterations in protein-DNA interactions in the γ-globin gene promoter in response to butyrate therapy. Blood. 1998;92:2924-2933.
45. Pace BS, Chen YR, Thompson A, Goodman SR. Butyrate-inducible elements in the human γ-globin promoter. Exp Hematol. 2000;28:283-293.
46. Boosalis MS, Bandyopadhyay R, Bresnick EH, et al. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood. 2001;97:3259-3267.
47. Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci U S A. 2001;98:1847-1852.
48. Safaya S, Ibrahim A, Rieder RF. Augmentation of gamma-globin gene promoter activity by carboxylic acids and components of the human beta-globin locus control region. Blood. 1994;84:3929-3935.
49. Holmes ML, Haley JD, Cerruti L, et al. Identification of Id2 as a globin regulatory protein by representational difference analysis of K562 cells induced to express γ-globin with a fungal compound. Mol Cell Biol. 1999;19:4182-4190.
50. Ryan TM, Sun CW, Ren J, Townes TM. Human γ-globin gene promoter element regulates human β-globin gene developmental specificity. Nucleic Acids Res. 2000;28:2736-2740.
51. Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci. 1998;850:38-44.
52. McDonagh KT, Nienhuis AW. Induction of the human γ globin gene promoter in K562 cells by sodium butyrate: reversal of repression by CCAAT displacement protein [abstract]. Blood. 1992;72:255a.
53. Pace BS, Chen YR, Thompson A, Goodman SR. Butyrate-inducible elements in the human gamma-globin protein. Exp Hematol. 2000;28:283-293.
54. Ginder GD, Singal R, Little JA, Dempsey N, Ferris R, Wang SZ. Silencing and activation of embryonic globin gene expression. Ann N Y Acad Sci. 1998;850:70-79.
55. Tanimoto K, Liu Q, Grosveld F, Bungert J, Engel JD. Context-dependent EKLF responsiveness defines the developmental specificity of the human epsilon-globin gene in erythroid cells of YAC transgenic mice. Genes Dev. 2000;14:2778-2794.
56. Lim S, Bieker J, Lin C, Costantini F. A shortened life span of EKLF-/- adult erythrocytes, due to a deficiency of beta-globin chains, is ameliorated by human gamma-globin chains. Blood. 1997;90:1291-1299.
57. Perkins AC, Sharpe AH, Orkin SH. Lethal β-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature. 1995;375:318-322.
58. Wijgerde M, Gribnau J, Trimborn T, et al. The role of EKLF in human β-globin gene competition. Genes Dev. 1996;10:2894-2902.
59. Perkins AC, Gaensler KM, Orkin SH. Silencing of human fetal globin expression is impaired in the absence of the adult β-globin gene activator protein EKLF. Proc Natl Acad Sci U S A. 1996;93:12267-12271.
60. Marin M, Karis A, Visser P, Grosveld F, Philipsen S. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growlh and differentiation. Cell. 1997;89:619-628.
61. Bouwman P, Gollner H, Elsasser HP, et al. Transcription factor Sp3 is essential for post-natal survival and late tooth development. EMBO J. 2000;19:655-661.
62. Van Loo PF, Bouwman P, Ling KW, et al. Impaired hematopoiesis in mice lacking the transcription factor Sp3. Blood. 2003;102:858-866.
63. Naar AM, Lemon BD, Tjian R. Transcriptional coactivator complexes. Annu Rev Biochem. 2001;70:475-501.
64. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell. 2002;108:475-487.
65. Blobel GA. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood. 2000;95:745-755.
66. Philipsen S, Suske G. A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res. 1999;27:2991-3000.
67. Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol. 2002;195:27-38.
68. Braun H, Koop R, Ertmer A, Nacht S, Suske G. Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res. 2001;29:4994-5000.
69. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature. 1977;268:462-464.
70. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. Modified histones in HeLa and Friend erythroleukemia cells treated with n-butyrate. Cold Spring Harb Symp Quant Biol. 1978;42:815-818.
71. McKnight GS, Hager L, Palmiter RD. Butyrate and related inhibitors of histone deacetylation block the induction of egg white genes by steroid hormones. Cell. 1980;22:469-477.
72. Chen X, Bieker JJ. Unanticipated repression function linked to erythroid Kruppel-like factor. Mol Cell Biol. 2001;21:3118-3125.
73. Doetzlhofer A, Rotheneder H, Lagger G, et al. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol. 1999;19:5504-5511.